Men's Health

A groundbreaking male contraceptive shows promising safety results, offering a reversible option for couples seeking effective birth control.

Pearls & Perspectives, hosted by Amy Pearlman, MD, is the latest multimedia program from Urology Times.

In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has important implications for urologists and the patients they treat.

The average life expectancy was 80.3 years among men with a total motile sperm count over 120 million, compared with 77.6 years among men with a total motile sperm count ranging from >0 to 5 million.

The FDA is requiring a warning about increased blood pressure and is recommending that the black box warning related to the increased risk of adverse cardiovascular events be removed.

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

"The biggest thing that I took away from using the device is that it allowed me to do the procedure by myself, without an assistant," says Matthew J. Mutter, MD.

The test can provide results in 48 minutes for diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.

New research better defines the link between cardiovascular disease risk and prevalence of ED per serum ceramide levels.

Data from a new SMSNA 2024 abstract show an association between significantly high BMI and risk of azoospermia and oligospermia.

“We saw in the survey that men are concerned with how the health decisions they make now will affect them in the future,” says Petar Bajic, MD.

"The updated guideline includes numerous new, important recommendations that will enhance the ability of urologists to provide optimal, state-of-the-art care for infertile males,” says Robert E. Brannigan, MD.

"We propose a new classification system, which we believe will provide a more consistent and standardized approach to classification and treatment of PD," says Landon Trost, MD.

“We get exposure and get an opportunity to work with experts in the field before we even start fellowship, so that we can develop a baseline of expertise in areas of Peyronie's disease, erectile dysfunction, infertility, and managing sexual medicine and fertility in men across the board,” says Jacob Rust, MD.

“It's been exciting to be on the forefront of new technology and new implants to help men regain their sexual function and empower them,” says Dr. Helen L. Bernie, DO, MPH.

“This is a great opportunity for public outreach and re-education on the common misconceptions surrounding vasectomy,” says Catherine S. Nam, MD.

“One thing is we’re trying to create an atmosphere in the center whereby men feel at ease, they're comfortable talking to their provider who is specialized in this field,” says Ramy Abou Ghayda, MD, MPH, MBA.

A decision on the NDS for testosterone undecanoate is expected in Q2 of 2025.

"Compared to the prior years, we found that there was a 150% increase in new vasectomy consults that were completed, and there was a 160% increase in the number of vasectomies that were done," says Catherine S. Nam, MD.

The study has enrolled 8 patients to assess the safety and efficacy of the device in sealed vasectomy procedures.

“Perhaps it's worth giving them questionnaires like the PHQ-9 or GAD-7 to monitor their mental health status and encourage or ask if they even have support around them,” says Olivia Paulsen.

“However, what direct to consumer does provide is convenience and privacy. Men's health has a huge stigma on it,” says Justin M. Dubin, MD.

"What we saw among over 400 patients [was] that indeed, subcutaneous heparin did not increase the hematoma chance, but it reduced the chance to have venous thrombotic events," says Thairo Pereira, MD.

“The association of lower testosterone concentrations with higher all-cause mortality was present irrespective of luteinizing hormone concentrations, indicating that low testosterone was the main factor," says Bu B. Yeap, MBBS, FRACP, PhD.

Data showed that 87.8% of treated patients and 96.1% of patients who completed the study achieved normal 24-hour mean plasma testosterone values (222 to 800 ng/dL) at 90-day follow-up.

The oral TRT study plans to enroll 20 male patients aged 18 to 49 years who meet the American Urological Association’s criteria for hypogonadism and who have not previously used TRT.

“In addition to the psychological and emotional burden associated with infertility, it's also been growing in incidence,” says Catherine S. Nam, MD.

“So, always going where the point of max curve is gives a much better outcome compared to if you're using any other technique,” says Landon Trost, MD.

The study is set to begin in January 2024.

“Sexual wellness is critical to overall health and happiness. That’s why you see more men and women turning to specialty health clinics for solutions to problems they consider more aesthetic versus medical,” said Mitchell Hollander, MD.